Company Participants
Andrew McKibben – Senior Vice President, Strategic Finance & Investor Relations
Christopher Peetz – CEO & Director
Nancy Shulman – Executive Vice President of Clinical
Peter Radovich – COO & President
Eric Bjerkholt – Chief Financial Officer
Rob Myers – Chief Medical Officer
Conference Call Participants
Yigal Nochomovitz – Citigroup Inc., Research Division
Ryan Deschner – Raymond James & Associates, Inc., Research Division
Joshua Schimmer – Cantor Fitzgerald & Co., Research Division
James Condulis – Stifel, Nicolaus & Company, Incorporated, Research Division
Brian Skorney – Robert W. Baird & Co. Incorporated, Research Division
Kalpit Patel – Wolfe Research, LLC
Joseph Thome – TD Cowen, Research Division
Yesha Patel – Evercore ISI Institutional Equities, Research Division
Jessica Fye – JPMorgan Chase & Co, Research Division
Avraham Novick – Morgan Stanley, Research Division
Lisa Walter – RBC Capital Markets, Research Division
Jonathan Wolleben – Citizens JMP Securities, LLC, Research Division
Swayampakula Ramakanth – H.C. Wainwright & Co, LLC, Research Division
Joseph Schwartz – Leerink Partners LLC, Research Division
Presentation
Operator
Good morning, and welcome to the Mirum Pharmaceuticals Business Update Call. My name is Hillary, and I will be your operator today. [Operator Instructions]
I would now like to hand the conference over to Andrew McKibben, SVP of Strategic Finance and Investor Relations. Andrew, please go ahead.
Andrew McKibben
Senior Vice President, Strategic Finance & Investor Relations
Thank you, Hillary, and good morning, everyone. I’d like to welcome you to Mirum’s conference call to discuss top line results from the Phase III portion of the AZURE-1 study of Brelovitug in chronic hepatitis delta, along with 48-week data from the Phase IIb portion of the study. For our prepared remarks, I’m joined today by our Chief Executive Officer, Chris Peetz; our Executive Vice President of Clinical Development, Nancy Shulman; and Peter Radovich, our President and